Galapagos NV Sponsored ADR GLPG 深 滬
等待開盤 02-07 09:30:00 美东时间
33.36
-0.020
-0.06%
華盛通- 最 高33.605
- 今 開33.38
- 成交量 7.12万股
- 最 低 33.17
- 昨 收 33.38
- 總市值 21.98亿
- 52周最高 37.78
- 市盈率 靜 27.43
- 換手率 0.11%
- 52周最低 22.591
- 委 比 -29.87%
- 總股本 6589.71万
- 歷史最高 274.03
- 量 比 0.70
- 振 幅 1.30%
- 歷史最低 13.023
- 每 手 1
- 風險率 3.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Galapagos To Wind Down Cell Therapy Business After Works Council Approval, Impacting ~365 Jobs And Closing Multiple Global Sites
Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to
01-06 05:02
Galapagos' GLPG3667 Meets Primary Endpoint In Dermatomyositis Study, Shows Mixed Results In Lupus Phase 3-Enabling Trials; Galapagos Will Evaluate All Strategic Alternatives, Including Resumption Of Its Partnering Process, To Accelerate Further Development Of GLPG3667 In Dermatomyositis And Potentially Other Severe Auto-Immune Indications
GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placeboIn the systemic
2025-12-19 05:02
Galapagos Shares Updated ATALANTA-1 Results At ASH 2025 Showing High Response Rates And Durable Responses With GLPG5101 In MCL
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day
2025-12-08 15:42
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
RBC Capital Maintains Sector Perform on Galapagos, Raises Price Target to $32
RBC Capital analyst Brian Abrahams maintains Galapagos (NASDAQ:GLPG) with a Sector Perform and raises the price target from $28 to $32.
2025-11-08 03:04
Galapagos NV Strengthens Board with Strategic Appointments
Galapagos ( ($GLPG) ) has provided an announcement. On October 30, 2025, Galapa...
2025-10-31 04:59
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
2025-10-23 10:06
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
2025-10-22 10:10
Leerink Partners Upgrades Galapagos to Outperform, Raises Price Target to $40
Leerink Partners analyst Faisal Khurshid upgrades Galapagos (NASDAQ:GLPG) from Market Perform to Outperform and raises the price target from $29 to $40.
2025-10-22 04:43
